Free Trial

PureTech Health plc (NASDAQ:PRTC) Sees Significant Decline in Short Interest

PureTech Health logo with Medical background

PureTech Health plc (NASDAQ:PRTC - Get Free Report) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 8,100 shares, a decrease of 22.1% from the April 30th total of 10,400 shares. Approximately 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 5,200 shares, the short-interest ratio is currently 1.6 days.

Institutional Trading of PureTech Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Birch Hill Investment Advisors LLC purchased a new position in shares of PureTech Health during the fourth quarter valued at approximately $5,575,000. Pentwater Capital Management LP grew its position in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after acquiring an additional 9,449 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of PureTech Health during the 4th quarter valued at $823,000. 0.04% of the stock is currently owned by hedge funds and other institutional investors.

PureTech Health Stock Up 2.5%

Shares of PRTC traded up $0.47 during trading hours on Thursday, hitting $19.07. The company had a trading volume of 138 shares, compared to its average volume of 4,677. The stock's 50 day moving average price is $17.25 and its 200 day moving average price is $18.56. PureTech Health has a 52-week low of $13.30 and a 52-week high of $29.80.

About PureTech Health

(Get Free Report)

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

Recommended Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines